SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS
elmasry, D., AbdElghaffar, A., Elebeary, M., Aidaros, M., Shawky, N. (2022). SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS. EKB Journal Management System, 28(6.1), 45-51. doi: 10.21608/zumj.2019.15900.1424
doaa elmasry; Adel Saed AbdElghaffar; Mahmoud Elsayed Elebeary; Magdy Abdelhamed Aidaros; Nagwa Mohammed Shawky. "SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS". EKB Journal Management System, 28, 6.1, 2022, 45-51. doi: 10.21608/zumj.2019.15900.1424
elmasry, D., AbdElghaffar, A., Elebeary, M., Aidaros, M., Shawky, N. (2022). 'SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS', EKB Journal Management System, 28(6.1), pp. 45-51. doi: 10.21608/zumj.2019.15900.1424
elmasry, D., AbdElghaffar, A., Elebeary, M., Aidaros, M., Shawky, N. SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS. EKB Journal Management System, 2022; 28(6.1): 45-51. doi: 10.21608/zumj.2019.15900.1424

SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS

Zagazig University Medical Journal
Article 7, Volume 28, Issue 6.1, November 2022, Page 45-51  XML PDF (287.98 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.15900.1424
View on SCiNiTO View on SCiNiTO
Authors
doaa elmasry email 1; Adel Saed AbdElghaffar2; Mahmoud Elsayed Elebeary3; Magdy Abdelhamed Aidaros4; Nagwa Mohammed Shawky5
1neurology department, faculty of medicine, port said university, Egypt
2Neurology department,faculty of medicine,Zagazig university,Egypt
3Neurology department,faculty of medicine,Zagazig university
4neurology department,faculty of medicine,zagazig university
5clinical pathology department,faculty of medicine,zagazig university
Abstract
Background: Axonal degeneration is the main pathological cause of progressive neurological disability in multiple sclerosis.Serum phosphorylated neurofilament-heavy (pNF-H) can be a useful marker to monitor axonal injury in multiple sclerosis (MS), but we have to investigate their serum value in disease course, disability, radiological parameters and treatment response.

Aim of the Work
To ass whether serum pNF-H levels are related with clinical and paraclinical measures of disease severity and imaging of MS to approve this protein as a likely surrogate marker for axonal loss in MS patients.

Subjects and methods
Study included 40 patients and 40 healthy control, All patients in this study were subjected to full history taking and clinical examination including BMI, neurolological examination and scoring according to the Expanded disability status score (EDSS), routine laboratory investigations, measuring pNF-H levels

Results: the serum levels of pNF-H protein were higher in patients compared to healthy controls. The higher levels were in the progressive groups and these levels were significantly correlated with EDSS , body mass index, disease duration and age of the patients.

Conclusion The increase in pNF-H titer in the patients and during the progressive phase of the disease together with the correlation of pNF-H levels with all clinical scales indicate that cumulative axonal loss is responsible for persistant disability and that high pNF-H level is a poor prognostic value.
Keywords
Multiple sclerosis; axonal damage; neurofilament - H
Statistics
Article View: 243
PDF Download: 67